Amedisys (AMED) Tops Q4 EPS by 6c, Offers FY Guidance

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.91, $0.06 better than the analyst estimate of $0.85. Revenue for the quarter came in at $434.4 million versus the consensus estimate of $427.51 million.

GUIDANCE:

Amedisys sees FY2019 EPS of $3.98-$4.09, versus the consensus of $4.08. Amedisys sees FY2019 revenue of $1.94-1.98 billion, versus the consensus of $1.94 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen